Cancer therapy-induced intestinal injury: Mechanisms, clinical manifestations, and management strategies

doi:10.3748/wjg.120954

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 41

This Article

(18)

(16)

(0)

(1)

(297)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 7, 2026; 32(41): 120954
Published online Nov 7, 2026. doi: 10.3748/wjg.120954

Full Size Figure Download Figure

Figure 1 Mechanisms and treatment strategies for cancer therapy-induced intestinal injury. Left: Principal mechanisms underlying intestinal injury induced by chemotherapy, radiotherapy, targeted therapy, immunotherapy, and surgical treatment include reactive oxygen species generation, gut microbiota dysbiosis, epithelial barrier dysfunction, ischaemia, immune cell infiltration, and short-chain fatty acid reduction. Right: Key treatment strategies include symptomatic supportive care, mechanism-targeted interventions, and modulation of gut microbiota to restore intestinal homeostasis. TNF-α: Tumour necrosis factor-alpha; IL: Interleukin; ROS: Reactive oxygen species; EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor; VEGFR: Vascular endothelial growth factor receptor; SCFA: Short-chain fatty acid; IVIG: Intravenous immunoglobulin; FMT: Faecal microbiota transplantation. Created using BioRender.

Citation: Nan YL, Sun TH, Ren KJ, Min TH, Ma YY, Xie X, Deng XY, Peng YC, Liu YY, Tong SY, Wang W, Dang CX, Zhang H. Cancer therapy-induced intestinal injury: Mechanisms, clinical manifestations, and management strategies. World J Gastroenterol 2026; 32(41): 120954
URL: https://www.wjgnet.com/1007-9327/full/v32/i41/120954.htm
DOI: https://dx.doi.org/10.3748/wjg.120954

Nan YL, Sun TH, Ren KJ, Min TH, Ma YY, Xie X, Deng XY, Peng YC, Liu YY, Tong SY, Wang W, Dang CX, Zhang H. Cancer therapy-induced intestinal injury: Mechanisms, clinical manifestations, and management strategies. World J Gastroenterol 2026; 32(41): 120954 [DOI: 10.3748/wjg.120954]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.